Ashrafi G H, Piuko K, Burden F, Yuan Z, Gault E A, Müller M, Trawford A, Reid S W J, Nasir L, Campo M S
Division of Pathological Sciences, Institute of Comparative Medicine, University of Glasgow, Glasgow G61 1QH, UK.
Deutsches Krebsforschungszentrum, Forschungsschwerpunkt Angewandte Tumorvirologie, Im Neuenheimer Feld 242, Heidelberg, Germany.
J Gen Virol. 2008 Jan;89(Pt 1):148-157. doi: 10.1099/vir.0.83267-0.
Equine sarcoids are fibroblastic skin tumours affecting equids worldwide. While the pathogenesis is not entirely understood, infection with bovine papillomavirus (BPV) type 1 (and less commonly type 2) has been implicated as a major factor in the disease process. Sarcoids very seldom regress and in fact often recrudesce following therapy. Nothing is known about the immune response of the equine host to BPV. Given that the viral genes are expressed in sarcoids, it is reasonable to assume that vaccination of animals against the expressed viral proteins would lead to the induction of an immune response against the antigens and possible tumour rejection. To this end we vaccinated sarcoid-bearing donkeys in a placebo-controlled trial using chimeric virus-like particles (CVLPs) comprising BPV-1 L1 and E7 proteins. The results show a tendency towards enhanced tumour regression and reduced progression in the vaccinated group compared to control animals. Although promising, further studies are required with larger animal groups to definitely conclude that vaccination with CVLPs is a potential therapy for the induction of sarcoid regression.
马肉瘤是一种成纤维细胞性皮肤肿瘤，影响着世界各地的马科动物。虽然其发病机制尚未完全明确，但1型牛乳头瘤病毒（BPV-1，2型较少见）感染被认为是该疾病进程中的一个主要因素。肉瘤很少会自行消退，事实上在治疗后往往会复发。关于马宿主对BPV的免疫反应尚不清楚。鉴于病毒基因在肉瘤中表达，合理推测给动物接种针对所表达病毒蛋白的疫苗会诱导针对这些抗原的免疫反应，并可能导致肿瘤排斥。为此，我们在一项安慰剂对照试验中，使用包含BPV-1 L1和E7蛋白的嵌合病毒样颗粒（CVLP）对患有肉瘤的驴进行了疫苗接种。结果显示，与对照动物相比，接种组的肿瘤消退有增强趋势，进展有所减少。尽管前景乐观，但需要对更大的动物群体进行进一步研究，以明确得出接种CVLP是诱导肉瘤消退的潜在治疗方法这一结论。
